Suvecaltamide

DB19139InvestigationalSmall molecule

Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

Mechanism: Pharmacologically active on Voltage-dependent T-type calcium channel
Curator reviewed
Formula / weight: C₂₀H₂₃F₃N₂O₂ · 380.411 g/mol (avg)
Also known as: 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)benzeneacetamide · Benzeneacetamide, 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)-
Code names: CX-8998 · JZP-385 · MK-8998

Resolves to

Compound

UNIIMIA4WMP8QNCAS953778-58-0ChEMBLCHEMBL1684950

Structure

InChIKeyIQIKXZMPPBEWAD-CQSZACIVSA-NSMILESCC(C)C1=CC=C(CC(=O)N[C@H](C)C2=CC=C(OCC(F)(F)F)C=N2)C=C1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Suvecaltamide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account